The objective of our study was to better understand the protective effects of the mitochondria-targeted tetra-peptide SS31 against amyloid beta (Ab)-induced mitochondrial and synaptic toxicities in Alzheimer's disease (AD) progression. Using intraperitoneal injections, we administered SS31 to an AD mouse model (APP) over a period of 6 weeks, beginning when the APP mice were 12 months of age. We studied their cortical tissues after SS31 treatment and determined that SS31 crosses the blood brain barrier and reaches mitochondrial sites of free radical production. We also determined: (1) plasma and brain levels of SS31, (2) mRNA levels and levels of mitochondrial dynamics, biogenesis proteins and synaptic proteins, (3) soluble Ab levels and immunoreactivity of mutant APP and Ab levels and (4) mitochondrial function by measuring H 2 O 2 , lipid peroxidation, cytochrome c oxidase activity and mitochondrial ATP. We found reduced mRNA expression and reduced protein levels of fission genes, and increased levels of mitochondrial fusion, biogenesis and synaptic genes in SS31-treated APP mice relative to SS31-untreated APP mice. Immunofluorescence analysis revealed reduced full-length mutant APP and soluble/insoluble Ab levels in the SS31-treated APP mice. Sandwich ELISA assays revealed significantly reduced soluble Ab levels in the SS31-treated APP mice relative to the untreated APP mice. Mitochondrial function was maintained in the SS31-treated APP mice over the 6 weeks of SS31 treatment compared with mitochondrial function in the untreated APP mice. Our findings indicate that SS31 treatment reduces Ab production, reduces mitochondrial dysfunction, maintains mitochondrial dynamics and enhances mitochondrial biogenesis and synaptic activity in APP mice; and that SS31 may confer protective effects against mitochondrial and synaptic toxicities in APP transgenic mice.
Introduction
Alzheimer's disease (AD) is a progressive, degenerative disorder manifested by dementia in aged individuals (1) . Currently, over 46.8 million people live with AD-related dementia worldwide, and this number is estimated to increase to 131.5 million by 2050 (2) . AD-related dementia has huge economic consequences, with the total worldwide medical cost of dementia estimated at $818 billion in 2015. By 2018, AD, including AD-related dementia, is expected to become a trillion-dollar disease (2) . In addition to dementia, AD is associated with the loss of synapses, synaptic dysfunction, mitochondrial structural and functional abnormalities, inflammatory responses, neuronal loss, extracellular neuritic plaques and intracellular neurofibrillary tangles (1, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Despite the progress that has been made in better understanding AD pathogenesis, there are still no early detectable markers, drugs or agents that can delay or prevent AD.
Several decades of research have revealed that mitochondrial dysfunction and synaptic damage are early events in the AD disease process. Mitochondria play several key roles in synaptic maintenance (13) , including assisting in the generation of adenosine triphosphate (ATP) and the regulation of Ca 2þ , both of which are essential for neuronal viability. In the case of ATP generation, it has long been recognized that neuronal activity can stimulate oxidative phosphorylation. However, several studies found decreased mitochondrial ATP production in postmortem AD brains compared with brains from age-matched subjects who did not have AD (9) (10) (11) 14, 15) . Further, using AD transgenic mouse lines, studies have found reduced levels of mitochondrial ATP in AD-affected brain regions (cortex and hippocampus) (16) (17) (18) (19) (20) (21) (22) (23) (24) and in the primary neurons of AD transgenic mice and in neurons expressing mutant APP and Ab (25, 26) . These findings support mitochondrial dysfunction and oxidative stress as largely involved in AD pathogenesis. However, there are no pre-clinical studies, such as studies using AD mouse models (APPs), to determine whether particular mitochondria-targeted molecules, such as SS31, can reduce mitochondria-generated free radicals. If such molecules can be identified in pre-clinical studies, then clinical studies can be designed to determine whether these molecules can trigger a reduction in mitochondria-generated free radicals and synaptic ATP in persons with AD and whether, in turn, mitochondria and synaptic toxicities can be reduced or the progression of AD symptoms can be slowed. Synaptic damage and the loss of synapses are the best correlates of cognitive decline, and they are critical factors responsible for cognitive decline in aged individuals and in patients with AD (7, (9) (10) (11) (12) 15, 27, 28) . Using electron microscopy, several studies investigated the connection between synaptic loss and cognitive decline in AD (12, 28) . These researchers found a 25-30% decrease in synapses in the cortex and a 15-35% decrease in synapses per cortical neuron, suggesting the hypothesis that synaptic loss correlates with cognitive decline in AD patients more than does the number of Ab plaques, the number of intracellular neurofibrillary tangles, or the extent of neuronal loss. Several researchers investigating synaptic proteins in AD patients and healthy control subjects found fewer pre-and post-synaptic proteins in AD patients in comparison to control subjects, suggesting that pre-and post-synaptic proteins may be critically involved in AD progression (29) (30) (31) . However, there are no pre-clinical studies, using APPs and mitochondriatargeted molecules such as SS31 in AD.
Recent mitochondrial and Ab studies found Ab monomers and oligomers in mitochondrial membranes, in the neurons of postmortem brain specimens from AD patients and AD mice, and in neurons expressing mutant APP (18, (32) (33) (34) . Further, recent evidence from our lab (25, 26, 35) and others (36) (37) (38) suggest that impaired mitochondrial dynamics (increased mitochondrial fission and decreased fusion) is present in neurons affected by AD. Further, recent studies from our lab revealed that Ab interacts with Drp1, with a subsequent increase in free radical production, which in turn activates Drp1 and Fis1, and causes excessive mitochondrial fragmentation, defective transport of mitochondria to synapses, low synaptic ATP and synaptic dysfunction in AD neurons (26, 35) . Given the increase in free radical production and excessive fragmentation in mitochondria that are involved in AD, we hypothesize that drugs capable of reducing free radicals and/or decreasing excessive fragmentation in mitochondria may be an effective therapeutic approach to treat patients with AD.
Studies have been conducted to assess whether natural antioxidants are capable of preventing or delaying the onset of AD and its symptoms (11, 39) . These antioxidants have provided only limited success in the clinical trials of AD patients (11, 39) . There have also been multiple clinical trials to test the efficacy of antioxidants in AD patients; these antioxidants include vitamin E (11, 39) , epigallocatechin gallate, resveratrol, curcumin, pramipexole, latrepirdine, ubiquinone, lipoic acid, idebenone, Ginkgo biloba and N-acetylcysteine (40) . Many non-traditional antioxidants, such as VitC, VitE, beta carotene and G. biloba, are known to modulate glutathione levels in the brain. Glutathione is an antioxidant that has been found to be lower in AD neurons than in non-diseased neurons. Glutathione has been proposed as a potential treatment in AD (41) . Unfortunately, only a few clinical trials testing the efficacy of glutathione have yielded positive results, with several showing a negative association between antioxidant supplementation and positive outcomes. Research into the efficacy of traditional antioxidants in AD faces a variety of physiological challenges; include limited penetrating and crossing the blood brain barrier (15) .
Because oxidative damage in mitochondria is thought to drive mitochondrial dysfunction, investigators have begun assessing the efficacy of antioxidant therapies specifically designed to prevent or delay mitochondrial dysfunction. Several mitochondria-targeted antioxidants have been developed and are currently undergoing pre-clinical testing. Such antioxidants include MitoQ, MitoVitE, MitoPBN, MitoPeroxidase, glutathione choline esters, latripiridine and Szeto-Schiller (SS) peptides (7, 11, (42) (43) (44) (45) . One of the most promising mitochondriatargeted antioxidants from these studies is SS31 (7, 44) .
SS31 is a cell-permeable tetra-peptide. It was synthesized as a part of a series of SS peptides-SS02, SS19, SS20, SS31-that are characterized as opioid agonists (46, 47) . SS31 was found, in vitro, to inhibit lipid peroxidation and H 2 O 2 scavenging (47). Furthermore, SS31 was found to protect neurons from Ca 2þ -induced mitochondrial depolarization swelling, to release cytochrome c in isolated organelles, and to protect against ischemia reperfusion injury in the guinea pig heart (47). SS31 was also evaluated in rat models of islet cell transplantation (48), myocardial infarction (49), brain ischemia reperfusion (49) and ALS (50) . Strikingly, SS31 was found to be beneficial in all of these conditions.
We recently, evaluated SS31 in rodent cell models of AD, including Ab-treated neuroblastoma (N2a) cells and primary neurons from APP mice, in order to determine whether SS31 is protective against Ab toxicity in AD (25) . In N2a cells treated with Ab25-35, we observed a range of problems in the mitochondria. Mitochondrial fission genes and proteins were up-regulated, whereas fusion genes and proteins were downregulated. There was also an accumulation of small, apparently fragmented mitochondria within the N2a cell body. Further, Ab25-35 treatment was associated with increased H 2 O 2 production, decreased cytochrome oxidase activity (COX) activity, and decreased ATP (25) . In N2a cells treated with only SS31, we observed increased expression of mitochondrial fusion genes, decreased H 2 O 2 production, increased COX activity and increased ATP levels, suggesting that SS31 reduces mitochondrial dysfunction and oxidative stress (25) . Our lab also evaluated the efficacy of SS31, using primary neurons from APP mice. Primary neurons are known to be deficient in synaptic markers and to exhibit dendritic simplification due to excreted Ab and intracellular accumulation of oligomeric Ab (51) (52) (53) . We found that, in addition to synaptic loss, aged primary neurons from APP mice exhibited increased numbers of rounded and structurally damaged mitochondria. Further, we found significantly decreased anterograde moving mitochondria and defective mitochondrial function in APP primary neurons. On the contrary, we found restored mitochondrial transport and synaptic viability, and decreased the percentage of defective mitochondria in SS31 treated APP primary neurons, indicating that SS31 protects mitochondria and synapses from Ab toxicity in APP primary neurons. However, there are no studies focusing on whether SS31 treatment of AD mice affects mitochondrial and synaptic alterations.
In the current study, we sought to determine the protective effects of mitochondria-targeted molecule SS31 in 12-monthold APP mice. We administered SS31 using intraperitoneal injections for a period of 6 weeks and studied: (1) mitochondrial fission machinery and fusion activity, (2) free radical production, (3) mitochondrial biogenesis, (4) SS31 enhances synaptic activity, (5) mitochondrial function, (6) soluble Ab levels and (7) immunoreactivities of full-length APP and soluble/insoluble Ab.
Results

SS31, and plasma and brain levels in wild-type (WT) mice
To determine whether SS31 crosses the blood brain barrier and reaches mitochondria, using intraperitoneal injections we administered SS31 (5 mg/kg body weight) twice a week for 6 weeks in a 12-month-old C57BL6 mice (n ¼ 6). PBS-treated WT mice (n ¼ 5) served as our control. We euthanized and harvested the brains of all SS31-treated WT mice after they underwent 6 weeks of SS31 treatment. We also collected blood to determine SS31 levels in the plasma of both groups. As shown in Figure 1 , we found sufficient levels of SS31 in the plasma and brain in the SS31-treated mice, indicating that SS31 crosses the blood brain barrier and reaches neuronal mitochondria.
APP mice and SS31 treatment
After checking the BBB status, we administered SS31 (5 mg/kg body weight), twice a week for 6 weeks in 12-month-old APP mice (Tg2576 line) (n ¼ 5) and PBS-treated APP mice (n ¼ 5) as controls. After 6 weeks treatment, we euthanized all the mice, harvested brains for mRNA, protein levels, mitochondrial functional parameters and soluble Ab levels and immunoreactivity of full-length APP and soluble/insoluble Ab. mRNA levels in SS31-treated and untreated APP mice Mitochondrial dynamics genes. mRNA expression levels significantly decreased in Drp1, by 2.7-fold (P ¼ 0.001); and in Fis1, by 2.4-fold (P ¼ 0.04) ( Table 1) in APP mice relative to SS31 treated APP mice. In contrast, the fusion genes were significantly increased in the SS31-treated APP mice: Mfn1 by 3.0-fold (P ¼ 0.001), Mfn2 by 2.2 (P ¼ 0.04) and Opa1 by 2.1-fold (P ¼ 0.01). These observations indicate SS31 reduces fission machinery and enhances fusion activity in 12-month-old APP mice.
Mitochondrial biogenesis genes. As shown in Table 1 , significantly increased mRNA levels of mitochondrial biogenesis were found in the SS31-treated APP mice-PGC1a by 3.0 (P ¼ 0.001), Nrf1 by 3.4-fold (P ¼ 0.003), Nrf2 by 2.1-fold (P ¼ 0.01) and TFAM by 2.5-fold (P ¼ 0.004). These observations suggest that SS31 enhances mitochondrial biogenesis activity.
Synaptic genes. mRNA levels of synaptic genes were significantly increased in the SS31-treated APP mice: synaptophysin by 2.2-fold (P ¼ 0.004) and PSD95 by 5.1-fold (P ¼ 0.001) ( Table 1 ). These findings suggest that SS31 enhances synaptic activity in 12-month-old APP mice.
Immunoblotting analysis
To determine the protective effects of SS31 on mitochondrial dynamics and biogenesis, and synaptic proteins, we quantified Mitochondrial dynamics proteins. In the SS31-treated APP mice relative to the untreated APP mice, the mitochondrial fission proteins Drp1 (P ¼ 0.02) and Fis1 (P ¼ 0.01) ( Fig. 2A and B) were significantly reduced. Also in the SS31-treated APP mice, the mitochondrial fusion proteinsMfn1 (P ¼ 0.02) and Mfn2 (P ¼ 0.04) were significantly higher compared with the untreated APP mice. These findings suggest that SS31 affects mitochondrial dynamics in APP mice.
Synaptic proteins. Synaptophysin (P ¼ 0.03) and PSD95 (P ¼ 0.02) levels were significantly increased in the SS31-treated APP mice relative to the untreated APP mice ( Fig. 2A and B) .
Mitochondrial biogenesis proteins. In the SS31-treated APP mice, the mitochondrial biogenesis proteins PGC1a (P ¼ 0.003), Nrf1 (P ¼ 0.01), Nrf2 (P ¼ 0.002) and TFAM (P ¼ 0.001) were significantly higher relative to the untreated APP mice ( Fig. 3A and B ). This finding suggests SS31 enhances mitochondrial biogenesis activity.
Immunofluorescence analysis
Using immunofluorescence analysis, we assessed the localization and quantification of mitochondrial dynamics, mitochondrial biogenesis and synaptic proteins in SS31-treated and untreated APP mice.
Mitochondrial dynamics proteins. As shown in Figure 4A and B, significantly lower levels of Drp1 (P ¼ 0.01) and significantly higher levels of Mfn1 (P ¼ 0.02) and Mfn2 (P ¼ 0.01) were found in the SS31-treated APP mice relative to the untreated APP mice. These findings suggest SS31 alters mitochondrial dynamics proteins in APP mice.
Mitochondrial biogenesis. As shown in Figure 5A and B, we found significantly higher levels of the mitochondrial biogenesis proteins PGC1a (P ¼ 0.03), Nrf1 (P ¼ 0.001), Nrf2 (P ¼ 0.03) and TFAM (P ¼ 0.01) in the SS31-treated APP mice relative to the untreated APP mice, indicating that SS31 enhances mitochondrial biogenesis in APP mice.
Synaptic proteins. Significantly higher levels of synaptophysin (P ¼ 0.001) and PSD95 (P ¼ 0.002) were found in the SS31-treated APP mice relative to the untreated APP mice ( Fig. 6A and B), indicating that SS31 enhances synaptic activity by increasing proteins levels.
Mutant APP and Ab immunoreactivity
To determine whether SS31 reduces mutant APP and Ab levels in SS31-treated APP mice, we performed immunostaining and immunofluorescence analysis of midbrain sections from the SS31-treated mice. As shown in Figure 7A and B, significantly lower immunoreactivity levels were found in the SS31-treated APP mice (P ¼ 0.002) relative to the untreated APP mice, suggesting SS31 reduces mutant APP and soluble/insoluble Ab.
Soluble Ab levels in the SS31-treated and untreated APP mice
Using sandwich ELISA, we measured soluble Ab42 and Ab40 levels to determine the effects of SS31 on soluble Ab levels. As shown in Figure 8A and B, significantly lower levels of Ab42 (P ¼ 0.01) and Ab40 (P ¼ 0.02) were found in the SS31-treated APP mice relative to the untreated APP mice. These findings indicate that SS31 affects Ab levels in APP mice.
Mitochondrial function
Mitochondrial function was assessed in the SS31-treated APP mice by measuring H 2 O 2 , lipid peroxidation, cytochrome c oxidase activity and mitochondrial ATP. As shown in Figure 9A , significantly decreased levels of H 2 O 2 were found in the SS31-treated APP mice relative to the untreated APP mice (P ¼ 0.001). Similar to H 2 O 2 , 4-hydroxy-2-nonenol (HNE), an indicator of lipid peroxidation was significantly lower in the SS31-treated APP mice relative to the untreated APP mice (P ¼ 0.01) (Fig. 9B) . Significantly higher levels of COX were found in the SS31-treated APP mice (P ¼ 0.02) relative to the untreated APP mice (Fig. 9C ). In addition, significantly higher levels of mitochondrial ATP were found in the SS31-treated APP mice relative to the untreated APP mice (P ¼ 0.02) (Fig. 9D) . and Mfn2; and the synaptic proteins synaptophysin and PSD95. Drp1 (P ¼ 0.02) and Fis1 (P ¼ 0.01) were significantly reduced; and Mfn1 (P ¼ 0.02) and Mfn2 (P ¼ 0.04) were significantly higher in the SS31-treated APP mice relative to the untreated APP mice, indicating that SS31 protects against mutant APP and also against Abinduced mitochondrial dynamics toxicity. Synaptophysin (P ¼ 0.03) and PSD95 (P ¼ 0.02) were significantly higher in the SS31-treated APP mice relative to the untreated APP mice, indicating that SS31 enhances synaptic activity.
Discussion
The objective of our study was to understand the protective effects against mutant APP/Ab-induced mitochondrial and synaptic toxicities in AD progression. Lower mRNA expressions and protein levels of fission genes, and higher levels of mitochondrial fusion, mitochondrial biogenesis, and synaptic genes and proteins were found in the SS31-treated APP mice relative to the untreated APP mice. Immunoblotting and immunofluorescence analyses revealed reduced full-length mutant APP and Ab deposit levels in the SS31-treated APP mice. Sandwich ELISA assays revealed significantly reduced soluble Ab levels in the SS31-treated APP mice relative to the untreated APP mice. Mitochondrial function was maintained in the SS31-treated APP mice relative to the untreated APP mice. These findings suggest that SS31 can reduce Ab production, reduces mitochondrial dysfunction, maintains mitochondrial dynamics and enhances mitochondrial biogenesis and synaptic activity in APP mice. These findings have implications for the development of small molecule-based therapeutics for AD patients. 
SS31 levels in the plasma and brain
Assessing plasma and brain levels of a drug molecule is the initial step before using the molecules in clinical trials. In the current study, following SS31 treatment, we carefully monitored plasma levels. We tested two doses-2-and 5-mg of SS31 per kg body weight-and found that the WT mice tolerated SS31 well and showed no adverse reactions, and the 5 mg dose also resulted in more distinct beneficial effects. Other researchers also found the 5 mg dose of SS31 per kg body weight to be protective in a mouse model of ALS (SOD mouse model) (50) , in a mouse model of brain ischemia perfusion (49) and in a mouse model of myocardial infarction (49) .
As shown in Figure 1 , we found a 10:1 ratio of plasma to the brain tissues of the untreated WT mice, and we expect similar ratios in the SS31-treated APP mice. The 10:1 ratio was sufficient to determine cellular and molecular changes in the plasma from the APP mice.
SS31, mRNA levels and protein levels
Abnormal mitochondrial dynamics-increased fission and decreased fusion and increased production of free radicals and reduced synaptic activity-have been extensively reported in postmortem brain tissues from AD patients (25, 26, (35) (36) (37) (54) (55) (56) (57) . SS31 has been found to be capable of reducing and/or scavenging free radicals in the mitochondria and protecting mitochondria and neurons from aging-and Ab-induced oxidative insults (7) . Further, in cell culture studies, SS31 was found to reduce excessive mitochondrial fragmentation, to increase fusion, and to increase synaptic gene expressions (25, 26) . In the current study, we found reduced excessive mitochondrial fragmentation by decreasing Drp1 and Fis1 levels and enhanced mitochondrial fusion by increasing Mfn1, Mfn2 and Opa1 and enhanced synaptic activities by increasing the levels of synaptophysin and PSD95 in the SS31-treated APP mice relative to the untreated APP mice. Further, our protein data-reduced levels of Drp1 and Fis1, increased levels of Mfn1, Mfn2 and Opa1, and increased levels of synaptophysin and PSD95 in the SS31-treated APP mice-were similar to our mRNA data showing increased synaptic proteins in the SS31-treated APP mice. These findings strongly suggest that SS31 is a promising drug target to increase synaptic and mitochondrial functions in AD neurons since hallmark symptoms of APP (e.g. excessive free radical production, impaired mitochondrial dynamics and mitochondrial dysfunction) were reduced in the SS31-treated mice.
Reduced full-length APP and reduced Ab levels
It is well documented that an age-dependent increase in levels of full-length APP and Ab occurs in patients with AD (35, 42) and in APPs (54, 55, (58) (59) (60) (61) (62) . Further, age-and Ab-induced excessive production of free radicals is key factors known to damage mitochondrial and synaptic functions in AD neurons (11, 42, (63) (64) (65) (66) . In assessing the levels of full-length APP, soluble Ab and Ab deposits in the SS31-treated APP mice compared with the untreated APP mice, we found significantly reduced levels of soluble Ab, reduced levels of immunoreactivity mutant APP and reduced levels of Ab deposits. Taken together, these findings suggest that SS31 reduces mutant full-length APP and soluble Ab, and Ab deposits in APP mice.
Mitochondrial function
Synaptic ATP is critical for multiple synaptic functions at nerve terminals, including neurotransmitter release, neurite outgrowth, synaptic vesicle fusion and synapse formation. To maintain sufficient levels of ATP at a synapse, large numbers of functionally active mitochondria are required. In addition, active mitochondrial transport is an important factor in Represents the levels of soluble Ab42 and (B), the levels of Ab40 in the SS31-treated APP mice relative to the untreated APP mice. Significantly lower levels of Ab42 (P ¼ 0.01) and Ab40 (P ¼ 0.02) were found in the 12-month-old SS31-treated APP mice relative to the untreated APP mice.
neurons is defective in AD neurons. To maintain synaptic ATP, synapses require large numbers of functionally active mitochondria. Mitochondria are synthesized at the cell soma and travel along axons and dendrites to nerve terminals, the synapses. In a diseased state, such as AD, mitochondria accumulate in the perinuclear region of cytoplasm and do not move to synapses (26, 36, 37) . In other words, the transport of mitochondria to synapses is impaired in AD neurons, mainly due to increased free radical production in the mitochondria and excessive fragmentation of the mitochondria. In a study in which we sought to determine the protective effects of SS31 in APP mice. We found that APP neurons treated with SS31 exhibited significantly increased motile and anterograde movement of mitochondria relative to the untreated APP neurons, suggesting that, in AD neurons, SS31 reduces mitochondrial fragmentation and toxicity, and enhances mitochondrial transport and function (13, 26) . In the current study, in the SS31-treated APP mice, mitochondrial function increased. This increase may have been due to increased mitochondrial ATP, COX, reduced free radicals, and reduced oxidative stress that were found in the SS31-treated APP mice (Fig. 9) . Our mitochondrial functional data were, consistent with the gene expression and protein data of in the SS31-treated APP mice. In the presence of mutant APP and Ab, SS31 reduced free radicals and lipid peroxidation, and increased mitochondrial ATP and COX, suggesting that SS31 may be a promising drug molecule to treat patients with AD.
SS31 metabolizes quickly and disintegrate in cells (data not shown); as a result, constant administration of SS31 was necessary in order to maintain SS31 levels in the plasma and brain tissues of the SS31-treated APP mice. We found no adverse effects of the SS31 treatment thus far in our APP mice.
Future studies
In the future studies, we plan to assess SS31 in both preventive (2-8 months) and curative (12-18 months) stages in APP and tau mice, and will assess the cognitive behavior, biochemical/ molecular and ultrastructural analyses.
Materials and Methods
Mice, SS31 administration, and tissue preparation
We purchased an Ab pre-cursor protein (APP) mouse model (Tg2576) (Taconic Farms, NY, USA) and used for our experiments.
The APP mice were generated with the mutant human APP gene 695 amino acid isoform and a double mutation (Lys   670   Asn  and Met   671 Leu) (Swedish mutation) (59) . This mouse line exhibits an age-dependent appearance of Ab plaques, as well as the distribution of Ab plaque confined to the cerebral cortex and the hippocampus. The human APP transgene was maintained in C57BL6/SJL backgrounds. The APP mouse model has been found to exhibit cognitive impairment 6 months of age and older. To determine transgene-positive mice for human APP, we performed genotyping in accordance with our Institutional policy on genotype tissue collection, using DNA prepared from tail biopsy and PCR amplification, as described in Hsiao et al. (59) .
All of the mice were observed daily by a veterinary caretaker and also examined twice a week by laboratory staff. Any mice showing pre-mature signs of neurological deterioration were euthanized before experimentation, according to procedures for euthanasia approved by our university's Institutional Animal Care and Use Committee, and were not used in the study.
Using intraperitoneal injections, we administered SS31 (n ¼ 5) and/or PBS (n ¼ 5) in the APP mice (5 mg/kg body weight) twice a week for 6 weeks, beginning when the mice were 12 months of age. The beginning treatment at age 12 months of age was selected because at 12 months of age APP mice show Ab deposits. The two groups of mice were: (1) AP P þ SS31 (APP mice treated with SS31) and (2) APP mice not treat with SS31 (untreated). For the first 2 weeks of injections, the mice exhibited no neurological deterioration or ill health, and they showed no beneficial effects. Following the next 6 weeks of injections, we tested them to determine any ill or beneficial effects.
Assessment of plasma and brains levels following SS31 treatment
The APP mice (treated with SS31 and untreated) were decapitated. Their blood was collected in heparinized tubes and centrifuged at 2000g for 15 min at 4 C. Collected plasma (200 ml) was gently vortexed with acetonitrile (1.8 ml) for 30 s and centrifuged at 14 000g for 15 min. Supernatant was collected. The final supernatant underwent high performance liquid chromatography (HPLC) analysis. A fresh cortex brain sample was transferred to tared homogenization vials, and mass was recorded. Three zirconia spheres were added to each vial, and a 9-fold vol/mass of acetonitrile was added for 5 min, for homogenization. Homogenization was performed four times (30 s each) for each vial, using a Bead Bug Microtube Homogenizer, at 4000 vibrations/min. After each homogenization, the vials were iced for 5 min. After final homogenization, the vials were kept in a À 20 C freezer for 10 min and then were centrifuged at 14.8g for 15 min. Supernatants were transferred to Eppendorf vials for vacuum evaporation. Then each sample was reconstituted with 60 ml of 5% acetonitrile dissolved in water. Twenty microliter of the sample was injected for HPLC C18 column using the following HPLC conditions: Kinetex 5m XB-C-18 column 100A 50 mm Â 2.1 mm, column temperature 25 C. Eluent flow was used at 200 ml/min (a) with water and (b) with acetonitrile, each containing 0.1% of formic acid: 5% acetronitrile for 1 min followed by a 4-min ramp to 90% acetronitrile, which was maintained for 6 min before returning to 5% and equilibrating for 1 min. The Thermo Scientific Exactive Mass Spectrometer with High Resolution Orbitrap Detector was used with X-calibur software for instrument control, data analysis, and sample quantitation. A low-concentration level of standard solution SS31 was used in the range of 15-1000 pg/ml. For SS31 plasma analysis, 20 ml samples were injected manually and separated on a narrow bore column, using a mobile phase via a solvent delivery pump.
Quantitative real-time RT-PCR
Using the reagent TriZol (Invitrogen, City, ST, USA), total RNA was isolated from cortical tissues from the untreated APP mice and the SS31-treated APP mice. Using primer express software (Applied Biosystems, Carlsbad, CA, USA), we designed the oligonucleotide primers for the housekeeping genes b-actin and GAPDH; and for the mitochondrial structural genes; the fission genes Drp1 and Fis1; the fusion genes MFN1, MFN2 and Opa1; and the synaptic genes synaptophysin and PSD95. The primer sequences and amplicon sizes are listed in Table 2 . Using SYBRGreen chemistry-based quantitative real-time RT-PCR, we measured mRNA expression of the above-mentioned genes, as described in Manczak and Reddy (67).
The mRNA transcript level was normalized against b-actin and the GAPDH at each of # dilutions. The standard curve was the normalized mRNA transcript level, plotted against the logvalue of the input cDNA concentration at each dilution. To compare b-actin, GAPDH and neuroprotective markers, relative quantification was performed according to the (CT) method (Applied Biosystems). Briefly, the CT method involved averaging triplicate samples, which were taken as the CT values for bactin, GAPDH, and mitochondrial and synaptic genes. b-Actin normalization was used for determining mitochondrial dynamics, biogenesis and the synaptic genes because the b-actin CT values were similar for the SS31-treated mice and the untreated APP mice. The DCT-value was obtained by subtracting the average b-actin CT value from the average CT value of the synaptic mitochondrial genes and the mitochondrial structural genes. The DCT of the untreated mice was used as the calibrator. Fold change was calculated according to the formula 2 ÀnDDCT), where DDCT is the difference between DCT and the DCT calibrator value. To determine the statistical significance of mRNA expression, the CT value differences between the untreated APP mice and other lines of mice were used in relation to b-actin normalization. Statistical significance was calculated, using one-way ANOVA.
Immunoblotting analysis
To determine SS31 alters the protein levels of mitochondrial dynamics and the biogenesis of synaptic genes (those that showed altered mRNA expression, we performed immunoblotting analyses of protein lysates from the SS31-treated APP mice and the untreated APP mice, as described in Manczak and Reddy (67) . Twenty microgram protein lysates from cortical and hippocampal tissues of the SS31-treated and untreated mice were resolved on a 4-12% Nu-PAGE gel (Invitrogen). The resolved proteins were transferred to nylon membranes (Novax Inc., San Diego, CA, USA) and incubated for 1 h at room temperature with a blocking buffer (5% dry milk dissolved in a TBST buffer). The PVDF membranes were incubated overnight with the primary antibodies shown in Table 3 . The membranes were washed with a TBST buffer three times at 10-min intervals and were then incubated for 2 h with appropriate secondary antibodies, followed by three additional washes at 10-min intervals. Mitochondrial and synaptic proteins were detected with chemiluminescence reagents (Pierce Biotechnology, Rockford, IL, USA), and the bands from immunoblots were quantified on a Kodak Scanner (ID Image Analysis Software (Kodak Digital Science, Kennesaw, GA, USA). Briefly, image analysis was used to analyze gel images captured with a Kodak Digital Science CD camera. The lanes were marked to define the positions and specific regions of the bands. An ID fine-band command was used to locate and to scan the bands in each lane and to record the readings.
Immunofluorescence analysis and quantification
Immunofluorescence analysis was performed using midbrain sections from the SS31-treated APP mice and the untreated APP mice, as described in Manczak and Reddy (67) . Immunofluorescence analysis was performed for Drp1, Mfn1, Mfn2, PGC1a, Nrf1, Nrf2, TFAM, synaptophysin, PSD95 and mutant APP/Ab deposits. The sections were washed with warm PBS, fixed in freshly prepared 4% paraformaldehyde in PBS for 10 min, and then washed with PBS and permeabilized with 0.1% Triton-X100 in PBS. They were blocked with a 1% blocking solution (Invitrogen) for 1 h at room temperature. All sections were incubated overnight with primary antibodies (see Table 4 ). After incubation, the sections were washed three times with PBS, for 10 min each. The sections were incubated with a secondary antibody conjugated with Fluors 488 and 599 (Invitrogen) for 1 h at room temperature. The sections were washed three times with PBS and mounted on slides. Photographs were taken with a multiphoton laser scanning microscope system (Zeiss Meta LSM510). To quantify the immunoreactivity of mitochondrial and synaptic antibodies for each treatment, 10-15 photographs were taken at Â40 magnification. Statistical significance was assessed, using a one-way ANOVA for mitochondrial and synaptic and mitochondrial proteins.
Measurement of soluble Ab levels
The cerebral cortex of each APP mouse brain was snap-frozen on dry ice at the time of sacrifice and stored at À70 C until a homogenate was prepared. Briefly, protein cortical and hippocampal tissues from all groups of mice were homogenized in a tris-buffered saline (pH 8.0) containing protease inhibitors (20 mg/ml pepstatin A, aprotinin, phosphoramidon and leupeptin; 0.5 mM phenylmethanesulfonyl fluoride; and 1 mM ethyleneglycol-bis(flaminoethyl ether)-NN tetra-acetic acid). Samples were briefly sonicated and centrifuged at 10 000g for 20 min at 4 C. The soluble fraction was used to determine the soluble Ab by ELISA. For each sample, Ab1-40 and Ab1-42 were was measured using cortical tissues from the SS31-treated APP mice and the untreated mice, as described in Manczak and Reddy (67) . Briefly, H 2 O 2 production was measured in the mitochondria cortical tissues from all lines of mice. A BCA Protein Assay Kit (Pierce Biotechnology) was used to estimate protein concentration. The reaction mixture contained mitochondrial proteins (lg/ll), amplex red reagents (50 lM), horseradish peroxidase (0.1 U/ml), and a reaction buffer (1Â). The mixture was incubated at room temperature for 30 min, followed by spectrophotometer readings of fluorescence (570 nm). H 2 O 2 production was finally determined, using a standard curve equation expressed in nmol/lg mitochondrial protein. H 2 O 2 levels were compared between the SS31-treated and untreated APP mice.
Lipid peroxidation assay. Lipid peroxidates are unstable indicators of oxidative stress in the brain. The final product of lipid peroxidation is HNE. We measured HNE in cell lysates prepared from cortical tissues taken from the SS31-treated and untreated APP mice. We used an HNE-His ELISA Kit in order to measure HNE levels (Cell BioLabs, Inc., San Diego, CA, USA), as described in Manczak and Reddy (67) . Briefly, freshly prepared protein was added to a 96-well protein binding plate and incubated overnight at 4 C. It was then washed three times with a buffer.
After the last wash, the anti-HNE-His antibody was added to the protein in the wells, was then incubated for 2 h at room temperature, and again was washed three times. The samples were then incubated with a secondary antibody conjugated with peroxidase for 2 h at room temperature, followed by incubation with an enzyme substrate. Optical density was measured at 450 nm to quantify the level of HNE. Lipid peroxidation levels were compared between the SS31-treated and untreated APP mice. Cytochrome C oxidase activity (COX). COX was measured in cortical tissues from all lines of mice. Enzyme activity was assayed spectrophotometrically, using a Sigma Kit (SigmaAldrich, St. Louis, MO, USA) following manufacturer's instructions. Briefly, 2 lg protein lysate was added to 1.1 ml of a reaction solution containing 50 ll of 0.22 mM ferricytochrome c fully reduced by sodium hydrosulphide, Tris-HCl (pH 7.0), and 120 mM potassium chloride. The decrease in absorbance at 550 mM was recorded for 1-min reactions at 10-s intervals. COX was measured according to the following formula: mU/mg total mitochondrial protein ¼ (A/min sample À (A/min blank) Â 1.1 mg protein Â 21.84). Protein concentrations were determined following the BCA method. COX levels were compared between the SS31-treated and untreated APP mice.
ATP levels. ATP levels were measured in mitochondria isolated from cortical tissues of the SS31-treated and untreated APP mice, using an ATP determination kit (Molecular Probes). The bioluminescence assay was based on the reaction of ATP with recombinant firefly luciferase and its subtract luciferin. Luciferase catalyzes the formation of light from ATP and luciferin. It is the emitted light that is linearly related to the In the current study, ATP levels were measured from mitochondrial pellets using a standard curve method. The ATP levels were also compared between the SS31-treated and untreated APP mice.
